Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 2,991 | 325 | 2,522 |
| Samples | 351 | 61 | 270 |
| Peptides | 276 | 42 | 230 |
Function
CAMKK2 · Calcium/calmodulin dependent protein kinase kinase 2
The product of this gene belongs to the Serine/Threonine protein kinase family, and to the Ca(2+)/calmodulin-dependent protein kinase subfamily. The major isoform of this gene plays a role in the calcium/calmodulin-dependent (CaM) kinase cascade by phosphorylating the downstream kinases CaMK1 and CaMK4. Protein products of this gene also phosphorylate AMP-activated protein kinase (AMPK). This gene has its strongest expression in the brain and influences signalling cascades involved with learning and memory, neuronal differentiation and migration, neurite outgrowth, and synapse formation. Alternative splicing results in multiple transcript variants encoding distinct isoforms. The identified isoforms differ in their ability to undergo autophosphorylation and to phosphorylate downstream kinases. [provided by RefSeq, Jul 2012].
Isoforms & Proteins
12 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000404169 | Q96RR4 | 324 | 227 |
| ENST00000324774 | Q96RR4 | 297 | 215 |
| ENST00000402834 | Q96RR4 | 297 | 215 |
| ENST00000392474 | Q96RR4-7 | 291 | 200 |
| ENST00000337174 | Q96RR4-3 | 278 | 198 |
| ENST00000412367 | Q96RR4-3 | 278 | 198 |
| ENST00000347034 | Q96RR4-4 | 277 | 197 |
| ENST00000392473 | Q96RR4-2 | 275 | 195 |
| ENST00000538733 | Q96RR4-5 | 258 | 180 |
| ENST00000446440 | Q96RR4-6 | 255 | 177 |
| ENST00000545538 | F5GZ00* | 159 | 110 |
| ENST00000652382 | Q96RR4 | 2 | 2 |
Gene Properties
Recurrent Mutations
All 227 amino-acid changes on canonical ENST00000404169 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in CAMKK2 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in CAMKK2 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 5/40 12% | 0/0 0% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 5/133 4% |
| Endometrial Carcinoma | 1/42 2% | 15/612 2% |
| Hodgkins Lymphoma | 2/16 12% | 1/122 1% |
| Oral Cavity Carcinoma | 1/54 2% | 0/0 0% |
| Adrenocortical Carcinoma | 0/3 0% | 2/112 2% |
| Biliary Tract Carcinoma | 1/54 2% | 16/950 2% |
| Melanoma | 5/210 2% | 30/1899 2% |
| Thyroid Gland Carcinoma | 0/45 0% | 26/1592 2% |
| Osteosarcoma | 3/45 7% | 0/166 0% |
| Cervical Carcinoma | 0/35 0% | 6/422 1% |
| Non-Small Cell Lung Carcinoma | 10/304 3% | 11/1390 1% |
| Colorectal Carcinoma | 4/143 3% | 37/3239 1% |
| Glioblastoma | 1/98 1% | 0/0 0% |
| Gastric Carcinoma | 4/74 5% | 15/1809 1% |
| Non-Cancerous | 0/104 0% | 8/830 1% |
| Plasma Cell Myeloma | 2/44 5% | 1/305 0% |
| Meningioma | 0/3 0% | 2/252 1% |
| Esophageal Squamous Cell Carcinoma | 1/51 2% | 19/2550 1% |
| Head and Neck Carcinoma | 0/85 0% | 11/1574 1% |
| Other Solid Cancers | 2/94 2% | 8/1515 1% |
| Hepatocellular Carcinoma | 2/46 4% | 12/2210 1% |
| Bladder Carcinoma | 0/58 0% | 6/956 1% |
| Glioma | 1/52 2% | 11/2127 1% |
| Neuroendocrine Tumour | 1/154 1% | 3/577 1% |
| Pancreatic Carcinoma | 0/89 0% | 9/1611 1% |
| Esophageal Carcinoma | 0/23 0% | 4/769 1% |
| Ovarian Carcinoma | 3/109 3% | 2/998 0% |
| Kidney Carcinoma | 3/85 4% | 5/1862 0% |
| Squamous Cell Lung Carcinoma | 1/57 2% | 2/810 0% |
Mutation Distribution
Where CAMKK2 is mutated · all tissues, split by cell line vs tissue
How many mutations in CAMKK2 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 2,991 mutations in CAMKK2
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|